Compare · ATEC vs WST
ATEC vs WST
Side-by-side comparison of Alphatec Holdings Inc. (ATEC) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATEC and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.22B, about 18.1x ATEC ($1.23B).
- Over the past year, ATEC is down 32.7% and WST is up 40.5% - WST leads by 73.2 points.
- WST has been more active in the news (4 items in the past 4 weeks vs 1 for ATEC).
- ATEC has more recent analyst coverage (17 ratings vs 16 for WST).
- Company
- Alphatec Holdings Inc.
- West Pharmaceutical Services Inc.
- Price
- $8.01+1.14%
- $314.41-0.90%
- Market cap
- $1.23B
- $22.22B
- 1M return
- +14.92%
- +0.26%
- 1Y return
- -32.75%
- +40.47%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2006
- News (4w)
- 1
- 4
- Recent ratings
- 17
- 16
Alphatec Holdings Inc.
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to maximize patient outcomes; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System designed to improve surgical efficiency without compromising accuracy. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; solanas posterior cervico/thoracic fixation system and avalon occipital plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. Further, it develops EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is based in Carlsbad, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest ATEC
- SEC Form SD filed by Alphatec Holdings Inc.
- Director Valentine Keith bought $996,192 worth of shares (135,000 units at $7.38), increasing direct ownership by 139% to 232,271 units (SEC Form 4)
- SEC Form 10-Q filed by Alphatec Holdings Inc.
- Alphatec Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- ATEC Refinances Existing Debt with Inaugural Bank Facility
- ATEC Reports First Quarter Financial Results
- SEC Form DEFA14A filed by Alphatec Holdings Inc.
- SEC Form DEF 14A filed by Alphatec Holdings Inc.
- ATEC to Report First Quarter 2026 Financial Results on May 5, 2026
- SEC Form 4 filed by Marshall Tyson Eliot
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)